Elimination of residual undifferentiated induced pluripotent stem cells (iPSCs) using irradiation for safe clinical applications of iPSC-derived cardiomyocytes

• Published in: Biochemical and biophysical research communications Vol. 574; pp. 91 - 96
• Main Authors: Takeda, Maki, Ito, Emiko, Minami, Kazumasa, Harada, Akima, Mochizuki-Oda, Noriko, Sawa, Yoshiki, Miyagawa, Shigeru
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 15-10-2021
• Subjects: Human induced pluripotent stem cells; Irradiation; Stem cell therapy; Tumorigenicity; Human induced pluripotent stem cells; Irradiation; Tumorigenicity; Stem cell therapy
• ISSN: 0006-291X; 1090-2104
• DOI: 10.1016/j.bbrc.2021.08.065

A major concern in the clinical application of induced pluripotent stem cells (iPSCs) is the prevention of tumorigenesis after implantation. Stem cells with high proliferative and differentiation potential are sensitive to radiation. Therefore, we hypothesized that irradiation may selectively eliminate residual undifferentiated human iPSCs (hiPSCs) in a cell population containing differentiated cardiomyocytes derived from hiPSCs (hiPSCs-CMs) and thus reduce tumorigenicity in vivo. hiPSC-CMs were irradiated with X-rays, after which the cell proliferation, apoptosis, morphology, and gene expression were analyzed. The gene expression of Lin28A, Nanog, Oct3/4, and SRY-box 2 was significantly lower in the irradiation group than in the control group. Irradiated hiPSC-CMs showed no change in proliferation potency and morphology compared to untreated hiPSC-CMs. Furthermore, irradiation did not induce apoptosis of differentiated cardiomyocytes. No significant difference in the gene expression of cardiac-specific markers, including α-myosin heavy chain, cardiac troponin T, and NK2 Homeobox 5, was observed between the groups. Tumorigenicity tests using NOG mice showed less frequent tumor formation in the irradiation group than in the control group. Irradiation of hiPSC-CMs significantly reduced the number of undifferentiated hiPSC and the tumor formation, while minimizing any adverse effects on hiPSC-CMs, thereby enabling safe hiPSC-based treatment.
•Irradiation reduced Lin28A, Nanog, Oct3/4, and SRY-box 2 expression.•Irradiation did not alter the proliferation and morphology of hiPSC-CMs.•Irradiation did not induce apoptosis of differentiated cardiomyocytes.•Irradiation induced less frequent tumor formation in mice.